A federal judge has put a hold on any further proceedings in the massive, years-long nationwide legal action against Abbvie and other makers of so-called testosterone replacement therapy drugs, saying he wants to give both sides time to complete a potential settlement drug to permanently end the litigation.
Recent News About Heard Robins & Cloud LLP View More
A federal judge has knocked down a $140 million verdict against pharmaceutical maker AbbVie, ordering a new trial over a man’s claims AbbVie’s Androgel testosterone replacement therapy drug caused him to suffer a heart attack.
Verdict much lower, but AbbVie wants $3.2M award tossed in second testosterone class action test trial
North Chicago-based drugmaker AbbVie is resisting what it is calling a jury's “confused and inconsistent” $3.2 million verdict, after the company lost a second trial in Chicago federal court – one in which it was ordered to pay $147 million less than the first trial – over a man’s claims AbbVie allegedly failed to warn its product AndroGel could bring on a heart attack.